Related Experiment Video

Updated: May 24, 2026

Using Live Cell STED Imaging to Visualize Mitochondrial Inner Membrane Ultrastructure in Neuronal Cell Models
08:48

Using Live Cell STED Imaging to Visualize Mitochondrial Inner Membrane Ultrastructure in Neuronal Cell Models

Published on: June 30, 2023

Genetic ablation of neuronal mitochondrial calcium uptake impedes Alzheimer's disease progression

Pooja Jadiya1,2, Elena Berezhnaya1, Devin W Kolmetzky1

  • 1Aging + Cardiovascular Discovery Center, Department of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.

The EMBO Journal
|May 22, 2026
PubMed

Insights

Inhibiting mitochondrial calcium uptake in Alzheimer's disease (AD) neurons reduces key pathologies like amyloid-beta and tau tangles. This approach improves mitochondrial function and cognitive decline, offering a potential therapeutic strategy for AD.

Area of Science:

  • Neuroscience
  • Mitochondrial Biology
  • Neurodegenerative Diseases

Background:

  • Mitochondrial calcium overload is implicated in Alzheimer's disease (AD) pathogenesis.
  • Dysfunctional calcium handling contributes to neuronal damage and cognitive decline in AD.

Purpose of the Study:

  • To investigate the causal role of mitochondrial calcium (mCa2+) uptake in AD progression.
  • To evaluate the therapeutic potential of inhibiting the mitochondrial calcium uniporter (MCU) in AD models.

Main Methods:

  • Utilized loss-of-function genetic mouse models (3xTg-AD) with conditional deletion of the MCU.
  • Employed in vitro AD models with MCU knockdown.
  • Assessed Aβ and tau pathology, synaptic function, cognitive performance, mitochondrial Ca2+ content, redox balance, and autophagy.

Main Results:

  • Loss of neuronal MCU function reduced Aβ and tau pathology, synaptic dysfunction, and cognitive deficits in AD mice.
  • MCU knockdown in vitro decreased matrix Ca2+, redox imbalance, and mitochondrial dysfunction.
  • Preserved mitochondrial function rescued autophagic capacity and protected neurons from amyloidosis and cell death.
  • In vivo studies showed improved mitochondrial structure and function in AD mice lacking neuronal MCU.

Conclusions:

  • Inhibiting neuronal mitochondrial calcium uptake is a promising therapeutic strategy for Alzheimer's disease.
  • Targeting MCU can ameliorate core AD pathologies and neurodegeneration.
  • Restoring mitochondrial calcium homeostasis may reverse AD-associated functional deficits.

More Related Videos

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)06:41

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Published on: January 10, 2025

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons06:23

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons

Published on: October 30, 2018

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...